Search hospitals > Maryland > Bethesda
National Cancer Institute (NCI)
Claim this profileBethesda, Maryland 20814
Global Leader in Tumors
Global Leader in Cancer
Conducts research for Lymphoma
Conducts research for Breast Cancer
Conducts research for Melanoma
296 reported clinical trials
11 medical researchers
Summary
National Cancer Institute (NCI) is a medical facility located in Bethesda, Maryland. This center is recognized for care of Tumors, Cancer, Lymphoma, Breast Cancer, Melanoma and other specialties. National Cancer Institute (NCI) is involved with conducting 296 clinical trials across 313 conditions. There are 11 research doctors associated with this hospital, such as A P. Chen, John Glod, MD, Nirali N. Shah, and Brigitte Widemann, MD.Area of expertise
1Tumors
Global LeaderStage IV
Stage III
PD-L1 positive
2Cancer
Global LeaderStage IV
BRCA positive
Stage III
Top PIs
A P. ChenNational Institutes of Health Clinical Center2 years of reported clinical research
Expert in Cancer
Expert in Tumors
24 reported clinical trials
67 drugs studied
John Glod, MDNational Cancer Institute Pediatric Oncology Branch8 years of reported clinical research
Studies Brain Tumor
Studies Sarcoma
10 reported clinical trials
13 drugs studied
Nirali N. ShahNational Institutes of Health, Clinical Center7 years of reported clinical research
Studies Leukemia
Studies Acute Myeloid Leukemia
9 reported clinical trials
12 drugs studied
Brigitte Widemann, MDNational Cancer Institute3 years of reported clinical research
Studies Nerve Sheath Tumors
Studies Neurofibrosarcoma
2 reported clinical trials
2 drugs studied
Clinical Trials running at National Cancer Institute (NCI)
Renal Cell Carcinoma
Prostate Cancer
Tumors
Kidney Cancer
Bladder Cancer
Neurofibromatosis
Cancer
Melanoma
Prostate Adenocarcinoma
Lymphoma
Oral NKT2152
for Kidney Cancer
This trial is testing NKT2152, a new oral drug, in adults with a specific type of kidney cancer who have no other treatment options. It aims to find the safest dose and see if the drug can effectively fight the cancer.
Recruiting1 award Phase 1 & 213 criteria
Triple Drug Therapy
for Kidney Cancer
This phase II trial studies the effects of combination therapy with bevacizumab, erlotinib, and atezolizumab in treating patients with hereditary leiomyomatosis and kidney cancer that may have spread from where it first started to nearby tissue, lymph nodes, or distant parts of the body (advanced). Bevacizumab is in a class of medications called antiangiogenic agents. They work by stopping the formation of blood vessels that bring oxygen and nutrients to tumors. This may slow the growth and spread of tumors. Erlotinib is in a class of medications called kinase inhibitors. It works by blocking the action of a protein called EGFR that signals cancer cells to multiply. This helps slow or stop the spread of cancer cells. Immunotherapy with monoclonal antibodies, such as atezolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Combination therapy with bevacizumab, erlotinib, and atezolizumab may stabilize or shrink advanced hereditary leiomyomatosis and kidney cancer.
Recruiting1 award Phase 218 criteria
Similar Hospitals nearby
Select from list below to view details
Frequently asked questions
What kind of research happens at National Cancer Institute (NCI)?
National Cancer Institute (NCI) is a medical facility located in Bethesda, Maryland. This center is recognized for care of Tumors, Cancer, Lymphoma, Breast Cancer, Melanoma and other specialties. National Cancer Institute (NCI) is involved with conducting 296 clinical trials across 313 conditions. There are 11 research doctors associated with this hospital, such as A P. Chen, John Glod, MD, Nirali N. Shah, and Brigitte Widemann, MD.